timothy sykes logo
ImmunityBio’s Stock Surges Amidst Impressive Clinical Trial Results and Strategic Approvals Thumbnail
ADD US ONG Google News

ImmunityBio’s Stock Surges Amidst Impressive Clinical Trial Results and Strategic Approvals

BRYCE TUOHEY•UPDATED JAN. 22, 2026, 5:04 PM ET
Reviewed by Tim Sykes Fact-checked by Matt Monaco

ImmunityBio Inc.’s stock has been trading up by 7.51 percent amid investor optimism fueled by promising trial results.

  • There is accelerated approval from the Saudi FDA for ImmunityBio’s ANKTIVA, set to expand treatment reach in combination with immune checkpoint inhibitors for various cancers.

  • The company’s ongoing discussions with the FDA regarding ANKTIVA’s application signify strategic regulatory engagement to broaden therapeutic use without further trials.

  • A promising analysis of trial enrollment showed exceeded expectations, intending to submit a biologics license application by end-2026, indicating robust market activity and growth.

  • ImmunityBio is making strategic moves to enhance its footprint in the Middle East, maximizing ANKTIVA’s market potential through local partnerships.

Candlestick Chart

Live Update At 17:03:58 EST: On Thursday, January 22, 2026 ImmunityBio Inc. stock [NASDAQ: IBRX] is trending up by 7.51%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

ImmunityBio has been on a remarkable journey, showing impressive financial strides. The company reported a preliminary net product revenue of nearly $113 million for 2025, representing a 700% increase compared to the previous year. In the last quarter alone, revenue soared to approximately $38.3 million, a 20% rise over the previous quarter and a staggering 431% jump from the same timeframe in 2024. It seems the growth engine is in full throttle, largely driven by the soaring demand for its flagship product, ANKTIVA, which witnessed a 750% surge in unit growth in 2025.

Taking a closer look at the stock’s recent activity, the stock price trajectory painted a promising picture. The share price leaped from a modest starting point at the year-end 2025, climbing through the ranks to reach a notable $6.92 by Jan 20, 2026. The rally continued as shares peaked on Jan 22 at an impressive $7.34. This momentum, noted over a span of just a few days, underscores the strong positive sentiment among investors sparked by pivotal news of IBRX’s strategic and regulatory milestones.

Market Reactions: Clinical Progress and Global Expansion Fuels Growth

The energy surrounding ImmunityBio is palpable. Recent news has illuminated a path filled with opportunity and success. The robust advancements in clinical trials, notably the chemotherapy-free CD19 CAR-NK cell therapy, has ignited investor confidence. The therapy, targeting Waldenstrom’s lymphoma, demonstrated a durable response with 100% control rate, a success that translated to a 34% stock surge. This outcome not only promises better patient outcomes but affirms ImmunityBio’s potential in transforming cancer treatment landscapes.

Moreover, the sweeping regulatory approvals across various territories, including the recent nod from the Saudi FDA, extend ANKTIVA’s reach and market applicability. With an eye on furthering its Middle Eastern presence, ImmunityBio’s strategic collaboration efforts aim to enhance product delivery and accessibility, casting a wider net for potential revenue avenues.

The burgeoning clinical and regulatory landscape gives the company the leverage to face competitive pressures head-on. These strategic advances fit into a broader narrative that has investors rallying behind IBRX, looking towards sustained upward momentum in the future.

More Breaking News

Conclusion

In summary, ImmunityBio’s recent financial performance has woven a compelling narrative, one that reflects its powerful growth trajectory and ambitious strategic vision. The layering of impressive trial outcomes and strategic drug approvals offers a dual-edged sword for continued market advantage. Traders are justifiably optimistic, as evidenced by the stock’s buoyancy. As millionaire penny stock trader and teacher Tim Sykes, says, “Preparation plus patience leads to big profits.” This ethos underscores the importance of strategic foresight and meticulous preparation in seizing market opportunities. Moving forward, the company’s ability to capitalize on these gains will define its position within the healthcare sector, potentially paving the way for future breakthroughs in cancer immunotherapy. With its eyes set on geographic expansion and relentless innovation, ImmunityBio is shaping up to be a formidable player in the biotechnology arena—one that captures not only market value but also, significantly, confidence from all its stakeholders.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply

Spot the Next Big Runner

Click Here for a Millionaire's POV on Trading IBRX

SUBSCRIBE FOR ALERTS

JOIN 50,000+ ACTIVE TRADERS

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”